Celladon Corp., a San Diego-based biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, has held an approximately $10m second close of its recently announced funding (read here).
MPM Capital and LSP Life Sciences Partners have joined existing investors Pfizer Venture Investors, Lundbeckfond Ventures, Novartis Venture Funds, Hambrecht and Quist Capital Management, GBS Venture Partners, Enterprise Partners Venture Capital, Johnson & Johnson Development Corp., and Venrock.
The company intends to use the new capital to advance its lead investigational product candidate MYDICAR® for the treatment of advanced heart failure, as well as to further strengthen activities in Europe. To this latest end, Celladon will establish a subsidiary in The Netherlands.
Celladon is led by President and CEO Krisztina Zsebo Ph.D., and in conjunction with the financing, Todd Foley, Managing Director at MPM Capital, and Fouad Azzam Ph.D., General Partner at LSP Life Sciences Partners, have joined the company’s borad of Directors.